Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $18.14 million. The enterprise value is -$6.59 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 8.03 million shares outstanding. The number of shares has increased by 8.67% in one year.
| Current Share Class | 8.03M |
| Shares Outstanding | 8.03M |
| Shares Change (YoY) | +8.67% |
| Shares Change (QoQ) | +19.61% |
| Owned by Insiders (%) | 4.65% |
| Owned by Institutions (%) | 26.95% |
| Float | 6.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.06 |
| Forward PS | 41.84 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.99
| Current Ratio | 9.99 |
| Quick Ratio | 9.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.41% and return on invested capital (ROIC) is -36.08%.
| Return on Equity (ROE) | -54.41% |
| Return on Assets (ROA) | -33.07% |
| Return on Invested Capital (ROIC) | -36.08% |
| Return on Capital Employed (ROCE) | -53.13% |
| Weighted Average Cost of Capital (WACC) | 7.00% |
| Revenue Per Employee | $143,015 |
| Profits Per Employee | -$816,752 |
| Employee Count | 14 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.57% in the last 52 weeks. The beta is 0.50, so Lipocine's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -37.57% |
| 50-Day Moving Average | 3.77 |
| 200-Day Moving Average | 4.75 |
| Relative Strength Index (RSI) | 33.80 |
| Average Volume (20 Days) | 110,570 |
Short Selling Information
The latest short interest is 173,716, so 2.16% of the outstanding shares have been sold short.
| Short Interest | 173,716 |
| Short Previous Month | 154,115 |
| Short % of Shares Out | 2.16% |
| Short % of Float | 2.60% |
| Short Ratio (days to cover) | 0.19 |
Income Statement
In the last 12 months, Lipocine had revenue of $2.00 million and -$11.43 million in losses. Loss per share was -$1.97.
| Revenue | 2.00M |
| Gross Profit | 2.00M |
| Operating Income | -12.13M |
| Pretax Income | -11.43M |
| Net Income | -11.43M |
| EBITDA | -12.07M |
| EBIT | -12.13M |
| Loss Per Share | -$1.97 |
Full Income StatementBalance Sheet
The company has $24.73 million in cash and n/a in debt, with a net cash position of $24.73 million or $3.08 per share.
| Cash & Cash Equivalents | 24.73M |
| Total Debt | n/a |
| Net Cash | 24.73M |
| Net Cash Per Share | $3.08 |
| Equity (Book Value) | 22.83M |
| Book Value Per Share | 3.05 |
| Working Capital | 22.72M |
Full Balance SheetCash Flow
| Operating Cash Flow | -10.05M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 60,026 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.05M |
| FCF Per Share | -$1.25 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -605.86% |
| Pretax Margin | -571.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.67% |
| Shareholder Yield | -8.67% |
| Earnings Yield | -63.05% |
| FCF Yield | -55.40% |
Analyst Forecast
The average price target for Lipocine is $6.00, which is 165.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 165.49% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 111.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -6.07 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.07 |
| Piotroski F-Score | 1 |
